Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer — Stella

Home/Adenocarcinoma - GEJ/Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

View on ClinicalTrials.gov

Recruiting

Back to Adenocarcinoma - GEJ trials

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United Kingdom

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire

Key details

Phase

Safety & dosing

Sponsor

University of Southampton

Collaborators

Bristol-Myers Squibb

Enrollment target

~18 participants

Started

September 2021

Primary completion

July 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.